Sean Ustic, PharmD

Founder & CEO, SuperSlowPush™

I didn’t set out to build a medical device company. I set out to fix something that shouldn’t have been broken.

For more than 15 years, I’ve worked inside hospitals as a clinical pain management pharmacist. I’ve helped lead opioid stewardship programs, built safety protocols, and sat in the rooms where medication safety committees debate how to prevent harm.

We built guardrails everywhere — smart pumps, barcode scanning, electronic health record checks.

Except one place.

When an IV opioid is pushed manually at the bedside, it’s still dependent on human speed and variability. I saw nurses trying to “slow push” hydromorphone in chaotic emergency rooms. I saw oncology patients experience sudden dysphoria and nausea. I saw the tension between doing it safely and doing it quickly enough to keep up with workflow.

And I realized: this is the last unguarded step in IV medication safety.

SuperSlowPush™ was born from that gap.

It’s not a pump.
It’s not software.
It’s not complex.

It’s a nurse-first, low-tech device that standardizes slow IV push delivery — automatically — without adding programming, batteries, or workflow burden.

Every major safety innovation in hospitals reduced variability. This one does the same thing for IV opioids.

We’ve partnered with Stratus Human Factors Engineering to build it right from day one — usability validation, FDA alignment, risk control strategy. USF has stepped in to take on the non-provisional patent, strengthening our IP position.

This isn’t theoretical. Hospitals already dilute opioids into IV piggyback bags to slow delivery because they know rapid push increases side effects and misuse risk. But that solution is expensive, labor-heavy, and not scalable.

We are the elegant middle path.

I’m not a first-time founder chasing an idea.
I’m a systems insider fixing a problem I’ve owned for years.

And because I understand hospital workflow, medication safety committees, and value analysis procurement — we’re not just building a device.

We’re building something hospitals will actually adopt.

SuperSlowPush™ — One Page Investor Summary
THE PROBLEM
100M+ IV opioid doses annually. >50% delivered too fast (<30 sec).
~1% adverse events → $2.7B–$5.2B annual hospital cost.
No system controls delivery speed at bedside.
THE SOLUTION
Disposable device that standardizes IV delivery to ~10 minutes.
No pump. No programming. Fits existing workflow.
Reduces side effects without reducing analgesia.
MARKET
$2.5B U.S. recurring market.
3,000+ hospitals.
$150K–$450K annual revenue per hospital.
VALIDATION

13 BayCare hospitals adopted a workaround to slow IV push.
Prototype validated. Human factors testing underway.
USF clinical collaboration.
ECONOMIC IMPACT
Category Current State With SuperSlowPush
Adverse Event Cost $4,000/event Reduced events
Event Rate ~1% Lowered
Labor Time Manual push time Reduced
Per Dose Cost $0 $25
Net Impact Hidden cost Net savings potential

BUSINESS MODEL
$25 single-use disposable.
Recurring high-volume use.
Offsets via risk + labor savings.
ASK
Raising $300K to reach clinical validation.
Unlocking $2M+ NIH HEAL and DoD grants.
12-month runway to pilot.